Zielinski, R.R. et al. 2014. Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer. Canadian Urological Association Journal. 8, 7-8 (Aug. 2014), e520–3. DOI:https://doi.org/10.5489/cuaj.2076.